Actively striving for the early and pilot implementation of new therapies, Zhejiang issued a document to promote the development of the pharmaceutical industry! China's stem cell industry accelerated forward!
May 6, Zhejiang Province, the Department of Economic and Information Technology, the Provincial Development and Reform Commission, the Provincial Department of Science and Technology, the Provincial Department of Finance, the Provincial Health Commission, the Provincial Health Insurance Bureau, the Provincial Bureau of Pharmaceutical Supervision, jointly issued a “number of opinions on the promotion of high-quality development of the pharmaceutical industry in Zhejiang Province”.
Biological products are one of the fastest growing sub-sectors in the pharmaceutical industry in recent years, and also the pharmaceutical sub-sectors with the most innovative potential. In this field, the “Opinions” clearly support the immunotherapy, gene therapy, stem cell therapy and other emerging areas of technological innovation and industrial development, focusing on the promotion of antibody-based biotherapeutic drugs, recombinant protein drugs in short supply of clinical urgency, vaccines for the prevention and treatment of major diseases, nucleic acid drugs, gene therapy drugs and cell therapy drugs, such as product research and development and industrialization of results. Support enterprises to accelerate the creation and industrialization of new drugs based on clinical needs, and achieve technological breakthroughs and application promotion in key areas such as gene industry, cell industry, innovative vaccines, high-performance imaging equipment, and accurate and rapid diagnostic reagents.
Stem cells become anti-epidemic stars, and the biomedical industry accelerates forward!
Stem cells, as a new field of biomedicine, promote the repair of organism trauma and the management of diseases through stem cell transplantation, differentiation and tissue regeneration, changing the traditional treatment of many major intractable and difficult diseases, bringing subversive changes to the study of the mechanism of disease and clinical application.
In 2019, cell therapy was written into China's industrial structure adjustment guidance catalog for the first time, and the “wind vane” of industry development will guide cell therapy to accelerate the transformation from the laboratory to the market. 2020, at the beginning of the fight against the epidemic of neococcal pneumonia, stem cell technology has become a treatment with good clinical prospects for the treatment of neococcal pneumonia. The safety and effectiveness of stem cell technology has been verified by clinical and scientific research data, providing strong scientific and technological support to overcome the epidemic.
General Secretary Xi emphasized when inspecting the scientific research on the prevention and control of C.pneumonia in Beijing on March 2 that it is necessary to “strengthen the basic research in the field of life sciences and breakthroughs in key core technologies in healthcare, and accelerate the improvement of strategic scientific and technological strength and strategic reserve capacity in the field of disease prevention and control and public health”, which points out a specific direction for the advancement of scientific and technological research for the prevention and control of the epidemic and the development of the biomedical industry. The development of the biomedical industry pointed out the specific direction.
Many places issued a document to promote the innovative development of biomedicine!
April 8, the Guangdong Provincial Science and Technology Department, Guangdong Provincial Development and Reform Commission, Guangdong Provincial Department of Industry and Information Technology, Guangdong Provincial Department of Finance, Guangdong Provincial Health Commission, Guangdong Provincial Health Protection Bureau, Guangdong Provincial Local Financial Supervision Administration, Guangdong Provincial Bureau of Traditional Chinese Medicine, Guangdong Provincial Drug Administration, and other departments to jointly issue the “promotion of biopharmaceutical innovation and development of a number of policies and measures” (hereinafter referred to as “measures”), dedicated to promoting the development of biopharmaceutical innovation. (hereinafter referred to as “Measures”), which are committed to enhancing the original innovation capability and international competitiveness of biopharmaceuticals, promoting the high-quality development of biopharmaceutical science and technology and industry, and improving the governance of biosafety.
The Measures explicitly propose to support Shenzhen to refine and deepen the industries of high-performance medical devices, gene sequencing and bioinformatics analysis, cell therapy, etc., to cultivate the world's benchmark biomedical enterprises and research institutes, and to build a global curator of biomedical innovation and development. Organize the implementation of precision medicine and stem cells, new drug creation, Chinese medicine key technology and equipment, high-end medical devices and other key provincial special projects.
March 5, Shenzhen Development and Reform Commission website released “1 + 3” four to promote the biomedical industry to gather the heavy policy documents! Including “Shenzhen to promote the development of biomedical industry agglomeration of the guiding opinions” and “Shenzhen biomedical industry agglomeration development implementation program (2020-2025)” “Shenzhen biomedical industry development action plan (2020-2025)” “Shenzhen to promote the development of biomedical industry agglomeration of a number of measures,” the three supporting documents.
Shenzhen Municipal Party Committee Standing Committee meeting pointed out that: a profound understanding of life safety and biosafety in the field of major scientific and technological achievements is an important weapon of the country's important, and effectively strengthen the basic research in the field of life sciences and medical and health key core technology breakthroughs. The four freshly released documents contain many references to support for the development of the cell therapy industry.
The application prospect of stem cells and its value to improve human life and health is undoubtedly huge. As a major livelihood project that can escort human life and health and change the destiny of human beings, it is believed that stem cells and regenerative medicine industry will also usher in new development opportunities under the trend of rapid development of biomedical industry.
